FAVIPIRAVIR AS A POTENTIAL DRUG IN THE TREATMENT OF COVID-19
DOI:
https://doi.org/10.29121/granthaalayah.v8.i4.2020.2Keywords:
Favipiravir, Coronavirus, TherapyAbstract [English]
Favipiravir is a drug developed for use against influenza and has been used successfully in other infectious conditions. After being internalized in the cell, the substance is phosphoribosylated acting on the RNA polymerase, and thus inhibiting replication and RNA viruses. Thus, the present study aimed to discuss the potential use of favipiravir in coronovavirus infections. There have been few studies involving favipiravir in COVID 19, however there is a report of recovery in more than 70% of patients diagnosed with pneumonia. However, new studies need to be carried out, mainly randomized clinical trials, so that the potential use of favipiravir in coronoviruses is adequately grounded.
Downloads
References
Chang, C.; jianying, H.; zhenshun, C. M. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. PubPeer, 31 Mar 2020. DOI: https://doi.org/10.1101/2020.03.17.20037432
Furuta, Y.; komeno, T.; komeno, T. Nakaruma, N. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. Aug 2; 93(7): 449–463. 2017. DOI: https://doi.org/10.2183/pjab.93.027
Madelain, V.; mentre, F.; baize, S. Modeling favipiravir antiviral efficacy against emerging viruses: from animal studies to clinical trials. Pharmacometrics & Systems Pharmacology, 20 March 2020 DOI: https://doi.org/10.1002/psp4.12510
Bricker, T. L.; shafiuddin, M.; gounder, A. P. Therapeutic efficacy of favipiravir against Bourbon virus in mice. PLoS Pathog. 2019 Jun; 15(6). DOI: https://doi.org/10.1371/journal.ppat.1007790
Drugbank. Favipiravir. Disponível em: https://www.drugbank.ca/drugs/DB12466. Acessado em 02/04/2020.
Goldhilla, D. H.; velthuisc, A. J. W. Fletcher, R. A. The mechanism of resistance to favipiravir in influenza. PNAS | November 6| vol. 115, 2018. DOI: https://doi.org/10.1073/pnas.1811345115
AdhikarI, S. P.; meng, S.; wu, Y.; mao, Y. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infectious Diseases Of Poverty, [s.l.], v. 9, n. 1, p.9-29, 17 mar. 2020. DOI: https://doi.org/10.1186/s40249-020-00646-x
Who, World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report...3.14. 2020. DOI: https://doi.org/10.7175/cmi.v14i1.1467
Li, G.; clerc, E. D. Therapeutic options for the 2019 novel coronavirus (2019-nCoV), Nature Review, 10, 2020 DOI: https://doi.org/10.13070/mm.en.10.2867
Sahin, A.R.; erdogan, A.; dineri, Y. Novel Coronavirus (COVID-19) Outbreak: A Review of the Current Literature. EJMO;4(1):1-7. 2020. DOI: https://doi.org/10.14744/ejmo.2020.12220
Rui, W.; liao, C.; he, H.; hu, C. COVID-19 in Hemodialysis Patients: A Report of 5 Cases. American Journal of Kidney Diseases Available online 31 March 2020.
Li, Q.; guan, X.; wu, P.. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med; published online Jan 29, 2020.
Guo, Y. R.; cao, Q. D.; hong, Z. S. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Medical Research, [s.l.], v. 7, n. 1, p.2-10, 13 March. 2020. DOI: https://doi.org/10.1186/s40779-020-00240-0
Praja, M.; sarma, P.; shekhar, N.. Drug targets for corona virus: A systematic review. Indian Journal of Pharmacology (Vol. 52, Issue 1), 2020. DOI: https://doi.org/10.4103/ijp.IJP_115_20
Wang, D.; hu, B.; hu. C. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069
Dawei W.; bo, H.; chang, H. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. ;323(11):1061-1069. 2020 DOI: https://doi.org/10.1001/jama.2020.1585
Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020, 6736, 1–7 DOI: https://doi.org/10.1016/S0140-6736(20)30211-7
Delang, L.; abdelnabi, R.; nets, J. Favipiravir as a potential countermeasure against neglected and emerging RNA viroses. Antiviral Research Volume 153, May Pages 85-94, 2018. DOI: https://doi.org/10.1016/j.antiviral.2018.03.003
Janowski, A. B.; dudley, H..; wang, D. Antiviral activity of ribavirin and favipiravir against human astroviruses. Journal of Clinical Virology Volume 123, February, 2020. DOI: https://doi.org/10.1016/j.jcv.2019.104247
Shikari, K.; daikoku, T.; cheng, C. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacology & Therapeutics 22 February 2020. DOI: https://doi.org/10.1016/j.pharmthera.2020.107512
Dong, L.; Hu, S.; Gao, J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discoveries &Therapeutics.; 14(1)58-60) 2020. DOI: https://doi.org/10.5582/ddt.2020.01012
Downloads
Published
How to Cite
Issue
Section
License
With the licence CC-BY, authors retain the copyright, allowing anyone to download, reuse, re-print, modify, distribute, and/or copy their contribution. The work must be properly attributed to its author.
It is not necessary to ask for further permission from the author or journal board.
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
